RecruitingPhase 1/2

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

United States91 participantsStarted 2025-08-18

Plain-language summary

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. CAR T cell therapy directed at any target
✕. Prior BCMA-targeting therapy
✕. Prior treatment with any FDA approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.

What they're measuring

Phase 1b: Number of Participants With incidence and severity of Treatment-emergent Adverse Events

Timeframe: Through study completion, a minimum of 6 months

Phase 2: Proportion of Participants Experiencing a Complete Response

Timeframe: Through study completion, a minimum of 6 months

Trial details

NCT IDNCT07081646

SponsorAlexion Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-08-15

Contact for this trial

Alexion Pharmaceuticals, Inc. (Sponsor)

1-855-752-2356 clinicaltrials@alexion.com

View on ClinicalTrials.gov More Relapsed AL Amyloidosis trials